Associations of Polymorphisms in the Peroxisome Proliferator-Activated Receptor Gamma Coactivator-1 Alpha Gene With Subsequent Coronary Heart Disease: An Individual-Level Meta-Analysis

Background: The knowledge of factors influencing disease progression in patients with established coronary heart disease (CHD) is still relatively limited. One potential pathway is related to peroxisome proliferator–activated receptor gamma coactivator-1 alpha (PPARGC1A), a transcription factor linked to energy metabolism which may play a role in the heart function. Thus, its associations with subsequent CHD events remain unclear. We aimed to investigate the effect of three different SNPs in the PPARGC1A gene on the risk of subsequent CHD in a population with established CHD. Methods: We employed an individual-level meta-analysis using 23 studies from the GENetIcs of sUbSequent Coronary Heart Disease (GENIUS-CHD) consortium, which included participants (n = 80,900) with either acute coronary syndrome, stable CHD, or a mixture of both at baseline. Three variants in the PPARGC1A gene (rs8192678, G482S; rs7672915, intron 2; and rs3755863, T528T) were tested for their associations with subsequent events during the follow-up using a Cox proportional hazards model adjusted for age and sex. The primary outcome was subsequent CHD death or myocardial infarction (CHD death/myocardial infarction). Stratified analyses of the participant or study characteristics as well as additional analyses for secondary outcomes of specific cardiovascular disease diagnoses and all-cause death were also performed. Results: Meta-analysis revealed no significant association between any of the three variants in the PPARGC1A gene and the primary outcome of CHD death/myocardial infarction among those with established CHD at baseline: rs8192678, hazard ratio (HR): 1.01, 95% confidence interval (CI) 0.98–1.05 and rs7672915, HR: 0.97, 95% CI 0.94–1.00; rs3755863, HR: 1.02, 95% CI 0.99–1.06. Similarly, no significant associations were observed for any of the secondary outcomes. The results from stratified analyses showed null results, except for significant inverse associations between rs7672915 (intron 2) and the primary outcome among 1) individuals aged ≥65, 2) individuals with renal impairment, and 3) antiplatelet users. Conclusion: We found no clear associations between polymorphisms in the PPARGC1A gene and subsequent CHD events in patients with established CHD at baseline.

[1]  L. Saremi,et al.  Computational Analysis of Gly482Ser Single-Nucleotide Polymorphism in PPARGC1A Gene Associated with CAD, NAFLD, T2DM, Obesity, Hypertension, and Metabolic Diseases , 2021, PPAR research.

[2]  Á. Ortega,et al.  PGC-1α, Inflammation, and Oxidative Stress: An Integrative View in Metabolism , 2020, Oxidative medicine and cellular longevity.

[3]  S. Oka,et al.  Multiple Levels of PGC-1α Dysregulation in Heart Failure , 2020, Frontiers in Cardiovascular Medicine.

[4]  Marco Valgimigli,et al.  2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. , 2019, European heart journal.

[5]  Kanika Jain,et al.  Role of Platelet Mitochondria: Life in a Nucleus-Free Zone , 2019, Front. Cardiovasc. Med..

[6]  K. Safranow,et al.  PPARα, PPARδ and PPARγ gene polymorphisms in patients with unstable angina. , 2019, Gene.

[7]  Yan V. Sun,et al.  Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events , 2019, Circulation. Genomic and precision medicine.

[8]  Yan V. Sun,et al.  Subsequent Event Risk in Individuals With Established Coronary Heart Disease , 2019, Circulation. Genomic and precision medicine.

[9]  Eitezaz Mahmood,et al.  Decreased PGC-1α Post-Cardiopulmonary Bypass Leads to Impaired Oxidative Stress in Diabetic Patients. , 2019, The Annals of thoracic surgery.

[10]  C. López-Otín,et al.  The microRNA-29/PGC1α regulatory axis is critical for metabolic control of cardiac function , 2018, PLoS biology.

[11]  K. Cohen,et al.  Regulation of diabetic cardiomyopathy by caloric restriction is mediated by intracellular signaling pathways involving ‘SIRT1 and PGC-1α’ , 2018, Cardiovascular Diabetology.

[12]  C. Handschin,et al.  Moderate Modulation of Cardiac PGC-1α Expression Partially Affects Age-Associated Transcriptional Remodeling of the Heart , 2018, Front. Physiol..

[13]  J. Estall,et al.  Linking Metabolic Disease With the PGC-1&agr; Gly482Ser Polymorphism , 2018, Endocrinology.

[14]  Pim van der Harst,et al.  Identification of 64 Novel Genetic Loci Provides an Expanded View on the Genetic Architecture of Coronary Artery Disease , 2017, Circulation research.

[15]  S. Parikh,et al.  PGC1α in the kidney. , 2018, American journal of physiology. Renal physiology.

[16]  Zhiqiang Ma,et al.  PGC-1: The Energetic Regulator in Cardiac Metabolism. , 2018, Current issues in molecular biology.

[17]  J. Keaney,et al.  PGC-1α dictates endothelial function through regulation of eNOS expression , 2016, Scientific Reports.

[18]  D. Gutterman,et al.  Role of PGC-1α in Vascular Regulation: Implications for Atherosclerosis. , 2016, Arteriosclerosis, thrombosis, and vascular biology.

[19]  V. Senthong,et al.  Association of combined genetic variations in PPARγ, PGC-1α, and LXRα with coronary artery disease and severity in Thai population. , 2016, Atherosclerosis.

[20]  M. Feki,et al.  The Gly482Ser polymorphism of the peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) is associated with type 2 diabetes in Tunisian population. , 2015, Diabetes & metabolic syndrome.

[21]  J. Danesh,et al.  A comprehensive 1000 Genomes-based genome-wide association meta-analysis of coronary artery disease , 2016 .

[22]  A. Haley,et al.  O R I G I N a L I N V E S T I G a T I O N Open Access Cardio Vascular Diabetology , 2022 .

[23]  K. Jablonski,et al.  Common variation at PPARGC1A/B and change in body composition and metabolic traits following preventive interventions: the Diabetes Prevention Program , 2014, Diabetologia.

[24]  J. Danesh,et al.  Large-scale association analysis identifies new risk loci for coronary artery disease , 2013 .

[25]  Tanya M. Teslovich,et al.  Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes , 2012, Nature Genetics.

[26]  K. Mirzaei,et al.  An Exonic Peroxisome Proliferator-Activated Receptor-γ Coactivator-1α Variation May Mediate the Resting Energy Expenditure through a Potential Regulatory Role on Important Gene Expression in This Pathway , 2012, Lifestyle Genomics.

[27]  L. Velloso,et al.  PGC1α gene Gly482Ser polymorphism predicts improved metabolic, inflammatory and vascular outcomes following bariatric surgery , 2012, International Journal of Obesity.

[28]  A. Knowlton,et al.  Mitochondrial dynamics in heart failure. , 2011, Congestive heart failure.

[29]  F. Shaw,et al.  Roles of Oxidative Stress, Apoptosis, PGC-1α and Mitochondrial Biogenesis in Cerebral Ischemia , 2011, International journal of molecular sciences.

[30]  T. Wenz.  Mitochondria and PGC-1α in Aging and Age-Associated Diseases , 2011, Journal of aging research.

[31]  Thomas W. Mühleisen,et al.  Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease , 2011, Nature Genetics.

[32]  Issa J Dahabreh,et al.  Index event bias as an explanation for the paradoxes of recurrence risk research. , 2011, JAMA.

[33]  Xiangfeng Lu,et al.  Association of peroxisome proliferator‐activated receptor gamma coactivator 1 alpha (PPARGC1A) gene polymorphisms and type 2 diabetes mellitus: a meta‐analysis , 2011, Diabetes/metabolism research and reviews.

[34]  Mark I. McCarthy,et al.  A genome-wide association study in Europeans and South Asians identifies five new loci for coronary artery disease , 2011, Nature Genetics.

[35]  A. Jiang,et al.  PGC-1 Coactivators in Cardiac Development and Disease , 2010, Circulation research.

[36]  Wei Zhang,et al.  Effects of the Peroxisome Proliferator Activated Receptor‐γ Coactivator‐1α (PGC‐1α) Thr394Thr and Gly482Ser Polymorphisms on Rosiglitazone Response in Chinese Patients With Type 2 Diabetes Mellitus , 2010, Journal of clinical pharmacology.

[37]  J. Boer,et al.  Glucose levels and genetic variants across transcriptional pathways: interaction effects with BMI , 2010, International Journal of Obesity.

[38]  V. Nosikov,et al.  Association of the CYBA, PPARGC1A, PPARG3, and PPARD gene variants with coronary artery disease and metabolic risk factors of coronary atherosclerosis in a Russian population , 2010, Heart and Vessels.

[39]  C. Gu,et al.  Association and interaction of PPAR-complex gene variants with latent traits of left ventricular diastolic function , 2010, BMC Medical Genetics.

[40]  S. Sihag,et al.  PGC-1alpha and ERRalpha target gene downregulation is a signature of the failing human heart. , 2009, Journal of molecular and cellular cardiology.

[41]  U. Ekelund,et al.  PPARGC1A sequence variation and cardiovascular risk-factor levels: a study of the main genetic effects and gene × environment interactions in children from the European Youth Heart Study , 2009, Diabetologia.

[42]  J. Martínez,et al.  Enhanced short-term improvement of insulin response to a low-caloric diet in obese carriers the Gly482Ser variant of the PGC-1alpha gene. , 2008, Diabetes research and clinical practice.

[43]  Le-ming Fan,et al.  ASSOCIATION BETWEEN PPARGC1A GENE POLYMORPHISMS AND CORONARY ARTERY DISEASE IN A CHINESE POPULATION , 2008, Clinical and experimental pharmacology & physiology.

[44]  C. Zechner,et al.  Transcriptional coactivators PGC-1alpha and PGC-lbeta control overlapping programs required for perinatal maturation of the heart. , 2008, Genes & development.

[45]  O. Pedersen,et al.  The Gly482Ser genotype at the PPARGC1A gene and elevated blood pressure: a meta-analysis involving 13,949 individuals , 2008, Journal of applied physiology.

[46]  X. Adiconis,et al.  PPARGC1A Variation Associated With DNA Damage, Diabetes, and Cardiovascular Diseases , 2008, Diabetes.

[47]  채수진.  한국 여성 다낭성 난소증후군 환자에서 peroxisome proliferators-activated receptor-γ와 coactivator-1α 유전자 다형성 양상 , 2008 .

[48]  Y. Li,et al.  The impact of severity of hypertension on association of PGC-1α Gene with blood pressure and risk of hypertension , 2007, BMC cardiovascular disorders.

[49]  Chun-yan Fu,et al.  Polymorphisms of the peroxisome proliferator-activated receptor-γ coactivator-1α gene are associated with hypertrophic cardiomyopathy and not with hypertension hypertrophy , 2007, Clinical chemistry and laboratory medicine.

[50]  Huiyun Liang,et al.  Staying Current PGC-1 : a key regulator of energy metabolism , 2006 .

[51]  M. Ridderstråle,et al.  Increased risk of obesity associated with the variant allele of the PPARGC1A Gly482Ser polymorphism in physically inactive elderly men , 2006, Diabetologia.

[52]  S. O’Rahilly,et al.  Meta-analysis of the Gly482Ser variant in PPARGC1A in type 2 diabetes and related phenotypes , 2006, Diabetologia.

[53]  Christoph Handschin,et al.  Metabolic control through the PGC-1 family of transcription coactivators. , 2005, Cell metabolism.

[54]  Jiandie D. Lin,et al.  Transcriptional coactivator PGC-1 alpha controls the energy state and contractile function of cardiac muscle. , 2005, Cell metabolism.

[55]  T. Hansen,et al.  PGC-1α Gly482Ser Polymorphism Associates With Hypertension Among Danish Whites , 2005 .

[56]  P. O'Connell,et al.  Evidence of a novel quantitative-trait locus for obesity on chromosome 4p in Mexican Americans. , 2004, American journal of human genetics.

[57]  P. Edwards,et al.  Peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α) regulates triglyceride metabolism by activation of the nuclear receptor FXR , 2004 .

[58]  L. Tiret.  Gene-environment interaction: a central concept in multifactorial diseases , 2002, Proceedings of the Nutrition Society.

[59]  T. Hansen,et al.  Mutation analysis of peroxisome proliferator-activated receptor-γ coactivator-1 (PGC-1) and relationships of identified amino acid polymorphisms to Type II diabetes mellitus , 2001, Diabetologia.

[60]  Guillaume Adelmant,et al.  Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1 , 2001, Nature.

[61]  J. Saffitz,et al.  Peroxisome proliferator-activated receptor gamma coactivator-1 promotes cardiac mitochondrial biogenesis. , 2000, The Journal of clinical investigation.

[62]  Guillaume Adelmant,et al.  Activation of PPARγ coactivator-1 through transcription factor docking , 1999 .

[63]  P. Puigserver,et al.  A Cold-Inducible Coactivator of Nuclear Receptors Linked to Adaptive Thermogenesis , 1998, Cell.